MIRA Pharmaceuticals shares are trading higher after the company announced new preclinical data demonstrating that Mira-55 did not produce cannabinoid-like central nervous system side effects across a comprehensive battery of validated behavioral assays.

LABU

<p>MIRA Pharmaceuticals shares are trading higher after the company announced new preclinical data demonstrating that Mira-55 did not produce cannabinoid-like central nervous system side effects across a comprehensive battery of validated behavioral assays.</p>

benzinga_article

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Health Care Select Sector SPDR

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

iShares US Pharma

Invesco Biotechnology & Genome ETF

VG Health

Mira Pharmaceuticals

News